Sección SEOM de Evaluación de Resultados

Este Grupo tiene como objetivos recoger información sobre seguridad de las intervenciones en el mundo real; conocer cuál es el impacto de la inversión sanitaria en resultados de salud; aportar componentes, soluciones y herramientas para superar las barreras que impiden la implementación del real world data; recomponer la idea de innovación mediante el uso de real world data procedente de estudios postautorización y de la recogida sistemática y valorar nuevas formas de financiación de las intervenciones sanitarias. p>

Comité Ejecutivo

Artículos de la Sección

• Prognostic modeling of overall survival in metastatic pancreatic cancer: an inflammation‑based tool validated in PANTHEIA‑SEOM cohort
• Systemic inflammation response index (SIRI) predicts outcomes and chemotherapy benefit in metastatic pancreatic cancer: A study by the PANTHEIA- SEOM group

Artículos de interés

1. Comparison of Population-Based Observational Studies With Randomized Trials in Oncology
2. Effectiveness in the Absence of Efficacy: Cautionary Tales From Real-World Evidence
3. Electronic health records and patient registries in medical oncology departments in Spain
4. Target Trial Emulation for Regulatory and Clinical Decision Making in Cancer

Artículos de interés - Registro de Cáncer Esofagogástrico AGAMENON

1. On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry
2. Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer
3. Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab
4. Anthracycline-based triplets do not improve the efficacyof platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world datafrom the AGAMEMON National Cancer Registry
5. Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry
6. Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis
7. Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry
8. Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer
9. Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry
10. Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry
11. External validity ofidocetaxel triplet trials iniadvanced gastric cancer:  are there patients who still beneft?
12. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry
13. External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the  AGAMENON-SEOM registry
14. Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry
15. Causal Considerations Can Inform the Interpretation of Surprising Associations in Medical Registries
16. Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
17. Does HER2 status inluence in the beneit of ramucirumab and paclitaxel as second line treatment of advanced gastro‑esophageal adenocarcinoma? Data from the AGAMENON‑SEOM registry
18. The AGAMENON-SEOM model for  prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
19. Eicacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON‑SEOM registry
20. Is there a preferred platinum and luoropyrimidine regimen for advanced HER2‑negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry
21. Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis